Transcatheter aortic valve replacement emerged ≈20 years ago and changed the landscape of structural interventional cardiology. The first experiments in animal models provided proofs of the concept and the substrate for the first percutaneous valve implantation in patients. The initial promising results in a clinical setting drew the attention of the industry and of the scientific community, and an effort was made for the past 12 years to address the limitations of the technology, facilitate the procedure, minimize the risk of complications, and broaden the applications of transcatheter aortic valve replacement. This article reviews the evolution of transcatheter aortic valve replacement, presents the first steps in this field, cites the evidence from registries and clinical trials, highlights the limitations of this treatment, and discusses the future perspectives and the developments proposed to address the current pitfalls.
Christos V. Bourantas, Rodrigo Modolo, Andreas Baumbach, Lars Søndergaard, Bernard Prendergast, Muhidin Ozkor, Simon Kennon, Anthony Mathur, Michael Mullen, Patrick W. Serruys
Nicolas M. Van Mieghem, M.E.I. Schipper, Elena Ladich, Elham Faqiri, Robert van der Boon, Abas Randjgari, Carl Schultz, Adriaan Moelker, Robert‐Jan van Geuns, Fumiyuki Otsuka, Patrick W. Serruys, Renu Virmani, Peter P. de Jaegere
Discussion(0)
No comments yet. Be the first to comment.